سعر لينتارام 90 مجم 30 + 20 قرص 2022

Lintaram ticagrelor 90 mg film-coated tablets (Rameda, Egypt); antiplatelet (P2Y12 antagonist). Pack described as "30+20"; unit count not confirmed.

• To reduce the risk of CV death, MI and stroke in acute coronary syndrome or a history of MI (superior to clopidogrel for at least the first 12 months after ACS); also reduces stent thrombosis in stented ACS patients.Population: AdultsDailyMed (U.S. National Library of Medicine)
• To reduce the risk of a first MI or stroke in coronary artery disease at high risk (efficacy established in type 2 diabetes).Population: AdultsDailyMed (U.S. National Library of Medicine)
• To reduce the risk of stroke in acute ischaemic stroke (NIHSS 5 or less) or high-risk TIA.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (more than 5%): bleeding and dyspnoea.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• History of intracranial haemorrhage.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Active pathological bleeding (e.g. peptic ulcer, intracranial haemorrhage).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity (e.g. angioedema) to ticagrelor or any component.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning - bleeding risk: can cause significant, sometimes fatal bleeding; do not start in patients undergoing urgent CABG; manage bleeding without stopping if possible because discontinuation increases subsequent cardiovascular events.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• If temporary interruption is needed (e.g. major-bleeding-risk surgery) stop 5 days before and restart as soon as possible.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Dyspnoea occurs more often than with comparators and is self-limiting; false-negative platelet function tests for HIT have been reported.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A inhibitors (e.g. ketoconazole, itraconazole, voriconazole, clarithromycin, ritonavir) and strong CYP3A inducers (e.g. rifampin, phenytoin, carbamazepine, phenobarbital)Avoid: inhibitors increase bleeding/dyspnoea risk; inducers reduce efficacy.DailyMed (U.S. National Library of Medicine)
• OpioidsDelay and reduce ticagrelor absorption; consider a parenteral antiplatelet agent in ACS.DailyMed (U.S. National Library of Medicine)
• Simvastatin or lovastatin above 40 mg/day; rosuvastatin; digoxinHigher statin exposure and adverse-effect risk; monitor digoxin levels on starting or changing ticagrelor.DailyMed (U.S. National Library of Medicine)

• Case reports have not identified a drug-associated risk of major birth defects or miscarriage; structural abnormalities occurred in animal offspring at about 5-7 times the maximum human dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No human data; present in rat milk at higher concentrations than plasma; breastfeeding is not recommended.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Ticagrelor: Reversibly binds the platelet P2Y12 receptor, inhibiting ADP-mediated platelet activation and aggregation.